Glaucoma News and Research

Latest Glaucoma News and Research

Mimetogen Pharmaceuticals completes its equity financing

Mimetogen Pharmaceuticals Inc. ("Mimetogen"), a privately held drug development company announced today that it has successfully completed an equity financing, co-led by Boston-based VIMAC Milestone Medica Fund and Montréal-based iNovia Capital.

8 Oct 2009

Lions Eye Institute for Transplant & Research to study vision impairment and blindness

Real-time biomedical studies of factors leading to vision impairment are now possible through the world's largest ocular research center at Lions Eye Institute for Transplant & Research.

8 Oct 2009

Biovail provides update on its Phase III program with pimavanserin for Parkinson’s disease psychosis

Biovail Corporation today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with ACADIA Pharmaceuticals Inc. Following the announcement on September 1st of disappointing top-line results from the first Phase III PDP trial, Biovail and ACADIA remain committed to the successful development of pimavanserin and have established a development strategy that they believe will strengthen the PDP program.

7 Oct 2009

Early Phase II clinical trial for RK-023 to treat androgenetic alopecia

R-Tech Ueno, Ltd. has started early Phase II clinical trial for RK-023, a physiologically active fatty acid derivative developed by the company -- a new compound targeted as a treatment for androgenetic alopecia (male pattern baldness).

7 Oct 2009

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with Biovail Laboratories International SRL (“Biovail”), a subsidiary of Biovail Corporation.

6 Oct 2009

Researchers identify novel circulation within human eye that provides new insight into glaucoma

Researchers at the University of Toronto, St. Michael's Hospital and Sunnybrook Health Sciences Centre have discovered a previously unidentified form of circulation within the human eye which may provide important new insights into glaucoma, a leading cause of blindness.

6 Oct 2009

Bausch & Lomb announces acquisition of Tubilux Pharma's commercial assets

Bausch & Lomb, the global eye health company, today announced it has acquired the commercial assets of Tubilux Pharma S.p.A.

5 Oct 2009

Study finds that visual impairment in T1D patients may be decreasing

People diagnosed with type 1 diabetes (T1D) in recent years are less likely to develop diabetes-related vision loss than those diagnosed in earlier years, says a new study funded by the National Eye Institute, a division of the National Institutes of Health. Forecasts of visual impairment prevalence in T1D patients may need to be amended, the researchers suggest, since current predictions assume that the earlier incidence rates will continue.

3 Oct 2009

Falls are a major cause for eye injuries in the elderly

The most common fear for family members when an elderly relative falls is broken bones. But eye injuries can be just as serious and debilitating. Home is the where most eye injuries occur, and slips and falls are among the most common type of home injuries. Slippery stairs, loose railings, or sharp edges on furniture can lead to painful falls and devastating eye injuries for seniors, as well as children and other household members.

3 Oct 2009

Recession impacts health: AOA survey

While the economy begins to show signs of a slow recovery, many consumers continue to struggle with financial challenges, some of which could affect their health. A survey released today by the American Optometric Association (AOA) revealed that 36 percent of Americans say they are limiting their doctor visits because of the recession.

1 Oct 2009

UCF research team develops miniature diagnostic tool kit for dementia

With the risk of developing dementia growing at an alarming pace, a University of Central Florida research team is working with the Boston University School of Medicine to develop a miniature diagnostic toolkit in the hopes of stimulating earlier detection and treatment.

1 Oct 2009

ORBIS' Childhood Blindness Initiative aims to develop 50 pediatric ophthalmology centers across India

ORBIS International's flagship Flying Eye Hospital arrived in Jaipur, India with its international team of volunteer eye care specialists and global sponsor Alcon, Inc. (NYSE: ACL), the world's leading eye care company.

1 Oct 2009

Quintiles Transnational enter into marketing agreement with Allergan for SANCTURA XR

Quintiles Transnational Corp. and Allergan, Inc. (NYSE: AGN) today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR® (trospium chloride extended release capsules), an anticholinergic approved for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency, predominantly to primary care physicians in the United States.

28 Sep 2009

NIDCD awards research grant to Mobius Therapeutics

Mobius Therapeutics, LLC ™ has been awarded a research grant from the National Institute on Deafness and other Communication Disorders (NIDCD) to study its investigational procedure, selective Photodynamic Myringotomy (PDM).

25 Sep 2009

Rio Grande Dermatology offers eyelash drugs for $99

Many women desire to have thicker and longer eyelashes. Previously this could only be accomplished with the use of fake lashes. However, due to the discovery of a desirable side effect of a glaucoma drug, Latisse was born. Rio Grande Dermatology, providers of comprehensive dermatology treatments for the Albuquerque metropolitan area, is proud to offer this highly anticipated "eyelash drug" for an introductory price of $99 dollars.

24 Sep 2009

Congressional Black Caucus Spouses to host 4th Annual Community Health Breakfast

On September 24, 2009, the Congressional Black Caucus Spouses will continue their tradition of direct community involvement by hosting its 4th Annual Community Health Breakfast at So Others Might Eat (SOME) from 7 a.m. - 10:30 a.m., 71 O Street, NW, Washington, D.C.

23 Sep 2009

Gene variant discovery could lead to future glaucoma treatments

An international team, led by researchers from the University of California, San Diego School of Medicine and the National Eye Institute, has discovered gene variants for glaucoma in a black population. The finding could lead to future treatments or a cure for this disease, which leads to blindness in two million Americans each year.

22 Sep 2009

Lundbeck offers Sabril for treating children with infantile spasms in the U.S.

Lundbeck Inc. (“Lundbeck”), a wholly owned subsidiary of H. Lundbeck A/S in Denmark (Copenhagen: LUN), announced today that Sabril® (vigabatrin) Tablets and Powder for Oral Solution are now available for prescribing in the United States.

22 Sep 2009

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel™, Enzo’s oral, proprietary therapeutic for chronic autoimmune uveitis.

21 Sep 2009

Four single-letter variations in SNPs increse prostate cancer risk

deCODE genetics (Nasdaq: DCGN) today announced that a team of its scientists and academic colleagues from Finland, Spain, the Netherlands and the United States have today published the discovery of four novel single-letter variations in the sequence of the human genome (SNPs) conferring increased risk of prostate cancer.

21 Sep 2009

Glaucoma News and Research

Latest Glaucoma News and Research

Mimetogen Pharmaceuticals completes its equity financing

Lions Eye Institute for Transplant & Research to study vision impairment and blindness

Biovail provides update on its Phase III program with pimavanserin for Parkinson’s disease psychosis

Early Phase II clinical trial for RK-023 to treat androgenetic alopecia

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

Researchers identify novel circulation within human eye that provides new insight into glaucoma

Bausch & Lomb announces acquisition of Tubilux Pharma's commercial assets

Study finds that visual impairment in T1D patients may be decreasing

Falls are a major cause for eye injuries in the elderly

Recession impacts health: AOA survey

UCF research team develops miniature diagnostic tool kit for dementia

ORBIS' Childhood Blindness Initiative aims to develop 50 pediatric ophthalmology centers across India

Quintiles Transnational enter into marketing agreement with Allergan for SANCTURA XR

NIDCD awards research grant to Mobius Therapeutics

Rio Grande Dermatology offers eyelash drugs for $99

Congressional Black Caucus Spouses to host 4th Annual Community Health Breakfast

Gene variant discovery could lead to future glaucoma treatments

Lundbeck offers Sabril for treating children with infantile spasms in the U.S.

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

Four single-letter variations in SNPs increse prostate cancer risk

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Glaucoma News and Research

Latest Glaucoma News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in